Tango Therapeutics
TNGX
122 hedge funds and large institutions have $147M invested in Tango Therapeutics in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 39 reducing their positions, and 30 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 39
0.15% more ownership
Funds ownership: 99.09% → 99.24% (+0.15%)
11% less funds holding
Funds holding: 137 → 122 (-15)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
50% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 30
55% less capital invested
Capital invested by funds: $329M → $147M (-$182M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$4.52M |
| 2 |
Millennium Management
New York
|
+$3M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$1.5M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.17M |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
+$957K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.73M |
| 2 |
CC
Casdin Capital
New York
|
-$2.61M |
| 3 |
SCM
Superstring Capital Management
New York
|
-$1.47M |
| 4 |
BlackRock
New York
|
-$851K |
| 5 |
Goldman Sachs
New York
|
-$772K |
TNGX Hedge Fund Activity: Q1 2025 in Review
122 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q1 2025, worth a combined $147M — down 55% from $329M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of TNGX and 15 opened new positions — a net loss of 15 holders — while 39 trimmed existing stakes and 43 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $4.52M. The largest seller was Citadel Advisors, cutting an estimated $3.73M.
- 122 institutional investors held Tango Therapeutics (TNGX) as of Q1 2025, down from 137 in Q4 2024.
- Funds reported $147M of Tango Therapeutics stock for Q1 2025, down 55% quarter-over-quarter.
- 15 funds opened new Tango Therapeutics positions in Q1 2025 and 30 closed out, a net change of -15 holders.
- The largest Tango Therapeutics buyer in Q1 2025 was Marshall Wace, an estimated $4.52M added.
- The largest Tango Therapeutics seller in Q1 2025 was Citadel Advisors, an estimated $3.73M sold.
Based on aggregated 13F filings for Q1 2025.